



BioMed Research International

Special Issue on

**Biomarker Discovery in Fatty Liver Disease**

# CALL FOR PAPERS

Biomarker Discovery in fatty liver disease is a multifactor and multistep process which typically involves progression through different stages. The earliest stage is fatty liver; it is a reversible condition where a lot of fats accumulate in liver cells via the process of steatosis. It is common that it causes no symptoms and no complications; however, when it is getting serious, it can develop to more advanced liver injury, including steatohepatitis, fibrosis, cirrhosis, and even hepatocellular carcinoma. The identification and quantitation of clinically significant biomarkers are an expanding area of research which is able to extend diagnostic capabilities in hepatology.

Analytical methods have made a great contribution in biomarker discovery in metabolomics and proteomics. For example, liquid chromatography (LC), gas chromatography (GC), capillary electrophoresis (CE), mass spectrometry (MS), and nuclear magnetic resonance spectroscopy (NMR) have been used for molecule identification and quantitation for fatty liver disease biomarker discovery. High content and complicated data generated by instrument needs advanced bioinformatics system for data management and data analysis. Following molecule identification and quantification by chromatography and MS/NMR, fluorescent sensing and imaging have made a big progress in hepatocellular carcinoma study. We invite both basic and clinical researchers to submit original and review articles that will stimulate the efforts to biomarker discovery in fatty liver disease.

Potential topics include, but are not limited to:

- ▶ Metabolomics in diagnosis and biomarker discovery
- ▶ Proteomics and mass spectrometry technologies for biomarker discovery
- ▶ Analytical techniques including but not limited to LC/GC/CE/MS/NMR for identification and quantitation in fatty liver disease
- ▶ Multivariate analysis for metabolomics and proteomics data
- ▶ Machine learning and application in biomarker discovery
- ▶ Data processing for mass spectrometry based metabolomics
- ▶ Fluorescent sensing and imaging in hepatocellular carcinoma
- ▶ Fluorescent probes/sensors for the detection of guests associated with fatty liver diseases

Authors can submit their manuscripts via the Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/bmri/hepatology/bdld/>.

## Lead Guest Editor

Xue Shi, Coldstream Laboratories, Inc.,  
Lexington, USA  
[xueshisx@gmail.com](mailto:xueshisx@gmail.com)

## Guest Editors

Lin Xu, East China Normal University,  
Shanghai, China  
[lxu@chem.ecnu.edu.cn](mailto:lxu@chem.ecnu.edu.cn)

Xiaoli Wei, University of Louisville,  
Louisville, USA  
[xiaoli.wei@louisville.edu](mailto:xiaoli.wei@louisville.edu)

Yunping Qiu, Montefiore-Albert  
Einstein College of Medicine, New York,  
USA  
[yunping.qiu@einstein.yu.edu](mailto:yunping.qiu@einstein.yu.edu)

Xiaomei Zeng, StemCellLife LLC.,  
Richmond, USA  
[xzeng@stemcelllifellc.com](mailto:xzeng@stemcelllifellc.com)

## Manuscript Due

Friday, 26 February 2016

## First Round of Reviews

Friday, 20 May 2016

## Publication Date

Friday, 15 July 2016